T1	condition 43 72	neratinib-associated diarrhea
T2	eligibility 603 733	Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy
T3	intervention 753 762	neratinib
T4	control 777 784	placebo
T5	duration 789 798	12â€‰months
T6	outcome-Measure 800 806	Safety
T7	outcome-Measure 919 967	Health-related quality of life by diarrhea grade
T8	No-of-participants 1044 1077	Two thousand eight hundred sixtee
T9	intervention-participants 1086 1090	1408
T10	control-participants 1086 1090	1408
T11	outcome 1125 1147	Grade 3 and 4 diarrhea
T15	control-value 1230 1231	0
T16	intervention-value 1293 1298	28.6%
T17	outcome 1315 1329	grade 3 events
T18	outcome 1390 1431	cumulative duration of grade 3/4 diarrhea
T19	outcome 1486 1510	Serious diarrheal events
T20	intervention-value 1516 1518	22
T21	intervention-value 1520 1524	1.6%
T22	outcome 1530 1572	diarrheal events requiring hospitalization
T23	intervention-value 1578 1580	20
T24	intervention-value 1582 1586	1.4%
T12	intervention-value 1160 1163	561
T25	intervention-value 1165 1170	39.8%
T13	intervention-value 1176 1177	1
T26	intervention-value 1179 1183	0.1%
T14	control-value 1216 1218	23
T27	control-value 1220 1224	1.6%
